Skip to content
DraconiticResearch
Search Sources API
182,549 studies31 sourcesUpdated 47 min ago
Peer-reviewedCC BYeJHaem

Reversible Eltrombopag‐Associated Bone Marrow Fibrosis With Hematologic Recovery After Drug Withdrawal in ASXL1‐Mutated Hypoplastic Myelodysplastic Syndrome: A Case Report

  • Kyoko Yoshihara1
  • Ikuo Matsuda2
  • Yasuhito Nannya3
  • Mami Samori1
  • Naru Tomigaki1
  • Saki Takahashi1
  • Chisato Ohe2
  • Satoshi Yoshihara1
  1. 1Department of Hematology Hyogo Medical University School of Medicine Nishinomiya Japan
  2. 2Department of Surgical Pathology Hyogo Medical University School of Medicine Nishinomiya Japan
  3. 3Department of Hematology and Oncology The Institute of Medical Science The University of Tokyo Tokyo Japan
Read full textPDFDOICite

Abstract

Hypoplastic myelodysplastic syndrome (MDS) often overlaps clinically with aplastic anemia and frequently involves clonal hematopoiesis. Thrombopoietin receptor agonists (TPO‐RAs), including eltrombopag, are increasingly used to treat cytopenias in hypoplastic marrow failure syndromes; however, their long‐term effects on clonal dynamics and marrow fibrosis remain incompletely defined. We report a case of ASXL1‐ and TET2‐mutated hypoplastic MDS, initially managed as aplastic anemia, in which eltrombopag therapy was associated with a biphasic clinical course. Hematologic parameters initially improved with reduced transfusion requirements; however, prolonged exposure was followed by progressive marrow fibrosis (MF‐2 to MF‐3), worsening cytopenias, and expansion of a minor paroxysmal nocturnal hemoglobinuria (PNH) clone. Serum lactate dehydrogenase levels increased in parallel with fibrosis progression. After eltrombopag discontinuation, the patient achieved transfusion independence within 3 months and substantial regression of marrow fibrosis, accompanied by recovery of marrow cellularity exceeding the pretreatment baseline. Longitudinal molecular analysis demonstrated modest fluctuations in variant allele frequencies without evidence of overt unidirectional clonal progression. The temporal association between fibrosis progression and hematologic deterioration, together with sustained improvement after drug withdrawal, suggests that eltrombopag may have contributed to treatment‐associated microenvironmental remodeling that constrained hematopoiesis after an initial stimulatory phase. This case suggests that eltrombopag‐associated marrow fibrosis may be reversible even in the presence of clonal hematopoiesis, and that clinical worsening during TPO‐RA therapy does not necessarily indicate irreversible clonal evolution. Careful reassessment of marrow morphology, clonal dynamics, and treatment‐related niche perturbation may be warranted in patients with hypoplastic MDS who deteriorate during TPO‐RA therapy. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.

Related

  1. GATA2 Deficiency Presenting With a WHIM‐Like Phenotype and Subsequent Development of Monosomy 7‐Associated Myelodysplastic Syndrome in an Adolescent Female: A Case Report
    Aziz Eghbali, Meshkat Poortavakol, Hamideh Sadat Mirmohammadi
    Clinical case reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Pulmonary Leukocytoclastic Vasculitis Associated with Myelodysplastic Syndrome
    Ryota Ozawa, Midori Sato, Ryuto Ishikawa +7
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  3. Mortality trends and high-risk subgroups in hematologic malignancy-associated pulmonary embolism: a population-based analysis with complementary clinical data
    Xi Quan, Ping Zhang, Nan Zhang +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  4. The Norwood procedure in hypoplastic left heart syndrome with dextrocardia and situs solitus: Challenges that can be accepted
    Sameh M. Said, Ahmed Wahba, Yasin Essa
    JTCVS techniquesPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. Human iPSC-Derived Cardiomyocytes Maladaptively Remodel to Cyclic Stretch in Hypoplastic Left Heart Syndrome
    R. S. Verma, I. Zhang, X. Chen +3
    bioRxivPreprintAll rights reservedFull textPhysiologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{yoshihara2026reversible,
  title = {{Reversible Eltrombopag‐Associated Bone Marrow Fibrosis With Hematologic Recovery After Drug Withdrawal in ASXL1‐Mutated Hypoplastic Myelodysplastic Syndrome: A Case Report}},
  author = {Kyoko Yoshihara and Ikuo Matsuda and Yasuhito Nannya and Mami Samori and Naru Tomigaki and Saki Takahashi and Chisato Ohe and Satoshi Yoshihara},
  journal = {eJHaem},
  year = {2026},
  month = oct,
  doi = {10.1002/jha2.70393},
  url = {https://doi.org/10.1002/jha2.70393},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Reversible Eltrombopag‐Associated Bone Marrow Fibrosis With Hematologic Recovery After Drug Withdrawal in ASXL1‐Mutated Hypoplastic Myelodysplastic Syndrome: A Case Report
AU  - Kyoko Yoshihara
AU  - Ikuo Matsuda
AU  - Yasuhito Nannya
AU  - Mami Samori
AU  - Naru Tomigaki
AU  - Saki Takahashi
AU  - Chisato Ohe
AU  - Satoshi Yoshihara
PY  - 2026
DA  - 2026/10/27
JO  - eJHaem
DO  - 10.1002/jha2.70393
UR  - https://doi.org/10.1002/jha2.70393
AB  - Hypoplastic myelodysplastic syndrome (MDS) often overlaps clinically with aplastic anemia and frequently involves clonal hematopoiesis. Thrombopoietin receptor agonists (TPO‐RAs), including eltrombopag, are increasingly used to treat cytopenias in hypoplastic marrow failure syndromes; however, their long‐term effects on clonal dynamics and marrow fibrosis remain incompletely defined. We report a case of ASXL1‐ and TET2‐mutated hypoplastic MDS, initially managed as aplastic anemia, in which eltrombopag therapy was associated with a biphasic clinical course. Hematologic parameters initially improved with reduced transfusion requirements; however, prolonged exposure was followed by progressive marrow fibrosis (MF‐2 to MF‐3), worsening cytopenias, and expansion of a minor paroxysmal nocturnal hemoglobinuria (PNH) clone. Serum lactate dehydrogenase levels increased in parallel with fibrosis progression. After eltrombopag discontinuation, the patient achieved transfusion independence within 3 months and substantial regression of marrow fibrosis, accompanied by recovery of marrow cellularity exceeding the pretreatment baseline. Longitudinal molecular analysis demonstrated modest fluctuations in variant allele frequencies without evidence of overt unidirectional clonal progression. The temporal association between fibrosis progression and hematologic deterioration, together with sustained improvement after drug withdrawal, suggests that eltrombopag may have contributed to treatment‐associated microenvironmental remodeling that constrained hematopoiesis after an initial stimulatory phase. This case suggests that eltrombopag‐associated marrow fibrosis may be reversible even in the presence of clonal hematopoiesis, and that clinical worsening during TPO‐RA therapy does not necessarily indicate irreversible clonal evolution. Careful reassessment of marrow morphology, clonal dynamics, and treatment‐related niche perturbation may be warranted in patients with hypoplastic MDS who deteriorate during TPO‐RA therapy. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.
SN  - 2688-6146
ER  -